euro adhoc: Marseille-Kliniken AG / Financial Figures/Balance Sheet / - Turnover increases to EUR 58.0 million in Q1 2008/2009 - Net group income EUR 2.1 billion according to IFRS - Rehabilitation f

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

3-month report

10.11.2008

Berlin, 10 November 2008. Marseille-Kliniken AG (Prime Standard, ISIN
DE 0007783003, MKA) was able to further increase its operating
turnover by 5.8 % to EUR 58.0 m in the first quarter of the current
financial year (previous year: EUR 54.9 m). Net group income after
minority interest declined from EUR 7.0 m to EUR 2.1 m as planned due
to one-off effects (EUR 4.9 million) in the previous year´s quarter.
Per share this amounts to earnings of EUR 0.17 compared to EUR 0.57
in the previous year. EBIT/IFRS reached EUR 3.5 m after EUR 4.3 m in
the previous year. EBITDAR/IFRS amounted to EUR 17.0 m after the
previous figure of EUR 15.7 m. Equity was recorded at EUR 85.6 m
compared to EUR 82.4 m in the previous year. The equity ratio was
therefore increased to 37.4 % (previous year: 28.5 %).

Declining earnings can be mainly attributed to the fact that the
impacts of the corporation tax reform 2008 were factored into the
previous year´s results, which at that point resulted in a tax gain
of EUR 4.9 m. There were none of these or similar one-off effects in
the period under review.

Adjusted earnings according to DVFA/SG (IFRS) from the previous
year´s period amounted to EUR 4.8 m, and were almost reached in the
first quarter of the current financial year at EUR 4.7 m. This
amounts to EUR 0.39 per share (previous year: EUR 0.39). Adjusted
EBITDAR increased from EUR 16.8 m in the previous year to EUR 17.6 m,
while adjusted EBIT fell from EUR 6.6 m to EUR 5.8 m. Already high
occupancy levels at group level improved even further and with a
capacity of 9,100 beds (previous year: 8,801 beds) reached a value of
92.6 % compared to 92.3 % in the previous year. Adjustments mainly
relate to dormancy costs of currently unused facilities in the
Rehabilitation segment as well as start-up losses in eight care
institutions with 741 beds (9.5 % of capacity).

Capacity in Care increased from 7,518 to 7,794 beds as of the
reporting date. Turnover in the segment was up from EUR 43.0 m to EUR
44.9 m compared to the previous year. As expected earnings according
to DVFA/SG (IFRS) reached EUR 3.7 m compared to EUR 4.8 m in the
previous year. The causes mainly relate to higher energy costs and
general price increases for foodstuffs. Occupancy levels were down
slightly on the previous year at 93.1 % compared to 93.8 %.

The segment Rehabilitation is extremely successful. Capacity
increased to now 1,306 beds (previous year: 1,283 beds) as a result
of using 23 additional beds for Rehabilitation at the care clinic Bad
Schönborn. Segment turnover increased from EUR 11.9 m to EUR 13.1 m.
Earnings according to DVFA/SG (IFRS) increased considerably from
breaking even in the previous year to EUR 1.0 million. Restructuring
measures implemented are therefore showing sustained success. This is
also reflected in occupancy levels, which were up from 86.9 % in the
previous year to 92.6 %.

Given that developments are on plan in the period under review,
Marseille-Kliniken AG has a positive outlook for the future. A
continuing increase in occupancy levels, especially in expansion
institutions, will have a positive impact on turnover and earnings.
In addition to that, optimisation measures are going to result in
cost saving potentials being tapped in the current financial year.
For the full financial year 2008/2009 the company is confirming its
growth forecast, which is projecting an increase in turnover of 6.5 %
and an EBIT return of at least 7 %.

For more detailed information, please visit the website
www.marseille-kliniken.de to read the quarterly report.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marseille-Kliniken AG

Axel Hölzer

CEO

Alte Jakobstraße 79/80

10709 Berlin

Germany

Tel.: +49 30 / 246 32-400

Fax: +49 30 / 246 32-401

www.marseille-kliniken.de

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

Germany

Tel.: +49 40 / 320 279 10

Fax: +49 40 / 320 279 114

www.hillermann-consulting.de

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing